SEC Filing · S-3
Allogene Therapeutics, Inc.
ALLONASDAQEQUITYCurrent
SEC Filing
Company context
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Current securities
As-filed source
As filedOpen full document ↗